TRAW — Traws Pharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1130598 ·
Last close
$0.58
Market Cap
$8.90M
52W High
$3.27
52W Low
$0.43
ADV30
1,060,873
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -3,175,000 | -3,054,000 | 11,470,000 | 5,016,000 | 9,779,000 |
| Mar 2026 | 0 | — | -6,946,000 | -7,107,000 | 8,156,000 | 3,133,000 | 13,467,000 |
| Dec 2025 | 0 | — | -7,368,000 | -7,443,000 | 10,617,000 | 3,820,000 | 11,246,000 |
| Sep 2025 | 0 | — | -4,055,000 | -3,962,000 | 12,443,000 | 6,420,000 | 7,898,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,324,000
Investing CF
$-2,585,000
Financing CF
$5,088,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$1.11
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-647,091,000
Inventory
—
Receivables
$1,687,000
ST Investments
—
EBIT TTM
$-19,618,000
Pretax Income TTM
$-19,427,000
Interest Exp TTM
—
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-21,397,000
Free Cash Flow
$-13,326,000
Enterprise Value
$3,656,318
Total Cash
$5,016,000
Total Debt
$0
Shares Out
15,368,277
Trailing EPS
$-1.83
Book Value
$0.11
ROE
-433.4%
ROA
-99.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,790,000 | -17,875,000 | 9,170,000 | 10,617,000 | 11,246,000 | -629,000 | -18,185,000 |
| Dec 2024 | 226,000 | -24,910,000 | -166,523,000 | 24,962,000 | 56,592,000 | -31,630,000 | -29,792,000 |
| Dec 2023 | 226,000 | -20,298,000 | -18,948,000 | 22,683,000 | 12,011,000 | 10,672,000 | -17,932,000 |
| Dec 2022 | 226,000 | -19,627,000 | -18,964,000 | 39,372,000 | 11,063,000 | 28,309,000 | -16,294,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.88
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ENLV | Enlivex Ltd. | $8.99M | $0.51 | — |
| FBLG | FibroBiologics, Inc. | $9.06M | $1.36 | — |
| KALA | KALA BIO, Inc. | $8.71M | $0.45 | — |
| IMRN | Immuron Ltd | $9.36M | $1.16 | — |
| LNAI | Lunai Bioworks Inc. | $8.43M | $1.86 | — |
News headlines (Yahoo Finance, 1h cache)
Traws Pharma shares rise after Q2 loss comes in better than expected
2026-08-17 12:31 · Yahoo
Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights
2026-08-14 20:30 · Yahoo
Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program
2026-06-22 11:00 · Yahoo
Traws Pharma Shares Slide After UK Regulator Postpones Influenza Study
2026-06-15 10:26 · Yahoo
Traws Pharma Provides Regulatory Update on Influenza Program
2026-06-12 21:30 · Yahoo
Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks
2026-05-27 12:45 · Yahoo
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
2026-05-08 11:30 · Yahoo
Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights
2026-04-15 20:01 · Yahoo
Traws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
2026-04-20 13:55 · Yahoo
Traws Pharma Inc (TRAW) Q4 2025 Earnings Call Highlights: A Turnaround Year with Significant ...
2026-04-16 07:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.